Literature DB >> 29718739

Emerging therapeutic targets for treatment of leishmaniasis.

Shyam Sundar1, Bhawana Singh1.   

Abstract

INTRODUCTION: Parasitic diseases that pose a threat to human life include leishmaniasis - caused by protozoan parasite Leishmania species. Existing drugs have limitations due to deleterious side effects like teratogenicity, high cost and drug resistance. This calls for the need to have an insight into therapeutic aspects of disease. Areas covered: We have identified different drug targets via. molecular, imuunological, metabolic as well as by system biology approaches. We bring these promising drug targets into light so that they can be explored to their maximum. In an effort to bridge the gaps between existing knowledge and prospects of drug discovery, we have compiled interesting studies on drug targets, thereby paving the way for establishment of better therapeutic aspects. Expert opinion: Advancements in technology shed light on many unexplored pathways. Further probing of well established pathways led to the discovery of new drug targets. This review is a comprehensive report on current and emerging drug targets, with emphasis on several metabolic targets, organellar biochemistry, salvage pathways, epigenetics, kinome and more. Identification of new targets can contribute significantly towards strengthening the pipeline for disease elimination.

Entities:  

Keywords:  Leishmaniasis; drug discovery; drug targets; metabolic pathways; mitochondria

Mesh:

Substances:

Year:  2018        PMID: 29718739      PMCID: PMC6047532          DOI: 10.1080/14728222.2018.1472241

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  342 in total

1.  Leishmania tarentolae: a parallel isolation of cytochrome bc(1) and cytochrome c oxidase.

Authors:  A Horváth; E A Berry; L S Huang ; D A Maslov
Journal:  Exp Parasitol       Date:  2000-11       Impact factor: 2.011

2.  Antileishmanial and Cytotoxic Activity of Some Highly Oxidized Abietane Diterpenoids from the Bald Cypress, Taxodium distichum.

Authors:  C Benjamin Naman; Anthony D Gromovsky; Cory M Vela; Joshua N Fletcher; Gaurav Gupta; Sanjay Varikuti; Xiaohua Zhu; Emilia M Zywot; Heebyung Chai; Karl A Werbovetz; Abhay R Satoskar; A Douglas Kinghorn
Journal:  J Nat Prod       Date:  2016-02-23       Impact factor: 4.050

3.  Antibacterial and leishmanicidal activities of temporin-SHd, a 17-residue long membrane-damaging peptide.

Authors:  Feten Abbassi; Zahid Raja; Bruno Oury; Elodie Gazanion; Christophe Piesse; Denis Sereno; Pierre Nicolas; Thierry Foulon; Ali Ladram
Journal:  Biochimie       Date:  2012-10-29       Impact factor: 4.079

4.  Knockdown of LdMC1 and Hsp70 by antisense oligonucleotides causes cell-cycle defects and programmed cell death in Leishmania donovani.

Authors:  Puneet Raina; Sukhbir Kaur
Journal:  Mol Cell Biochem       Date:  2011-07-31       Impact factor: 3.396

5.  Cloning of a novel inosine-guanosine transporter gene from Leishmania donovani by functional rescue of a transport-deficient mutant.

Authors:  N S Carter; M E Drew; M Sanchez; G Vasudevan; S M Landfear; B Ullman
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

6.  The antileishmanial activity of novel oxygenated chalcones and their mechanism of action.

Authors:  L Zhai; M Chen; J Blom; T G Theander; S B Christensen; A Kharazmi
Journal:  J Antimicrob Chemother       Date:  1999-06       Impact factor: 5.790

7.  2-substituted quinoline alkaloids as potential antileishmanial drugs.

Authors:  A Fournet; A A Barrios; V Muñoz; R Hocquemiller; A Cavé; J Bruneton
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani.

Authors:  Susan Wyllie; Mark L Cunningham; Alan H Fairlamb
Journal:  J Biol Chem       Date:  2004-07-13       Impact factor: 5.157

9.  Impaired chromatin remodelling at STAT1-regulated promoters leads to global unresponsiveness of Toxoplasma gondii-infected macrophages to IFN-γ.

Authors:  Christine Lang; Anke Hildebrandt; Franziska Brand; Lennart Opitz; Hassan Dihazi; Carsten G K Lüder
Journal:  PLoS Pathog       Date:  2012-01-19       Impact factor: 6.823

10.  Apoptotic-like Leishmania exploit the host's autophagy machinery to reduce T-cell-mediated parasite elimination.

Authors:  Peter Crauwels; Rebecca Bohn; Meike Thomas; Stefan Gottwalt; Florian Jäckel; Susi Krämer; Elena Bank; Stefan Tenzer; Paul Walther; Max Bastian; Ger van Zandbergen
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

View more
  9 in total

Review 1.  Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.

Authors:  Shyam Sundar; Neha Agrawal; Bhawana Singh
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-06-17       Impact factor: 4.481

2.  In vitro efficacy of polymer coated miltefosine drug against leishmania tropica.

Authors:  Mehvish Khokhar; Muhammad Adnan Shereen; Momin Khan; Rahat Ullah Khan; Aamir Sohail; Imdad Ullah Khan; Inam Ullah Khan; Saadullah Khattak
Journal:  J Parasit Dis       Date:  2021-09-23

3.  Metalloprotease Gp63-Targeting Novel Glycoside Exhibits Potential Antileishmanial Activity.

Authors:  Amrita Chakrabarti; Chintam Narayana; Nishant Joshi; Swati Garg; Lalit C Garg; Anand Ranganathan; Ram Sagar; Soumya Pati; Shailja Singh
Journal:  Front Cell Infect Microbiol       Date:  2022-05-04       Impact factor: 6.073

4.  Nanomedicine-based strategies to improve treatment of cutaneous leishmaniasis.

Authors:  Nowsheen Goonoo; Marie Andrea Laetitia Huët; Itisha Chummun; Nancy Karuri; Kingsley Badu; Fanny Gimié; Jonas Bergrath; Margit Schulze; Mareike Müller; Archana Bhaw-Luximon
Journal:  R Soc Open Sci       Date:  2022-06-15       Impact factor: 3.653

Review 5.  Leishmania-Host Interactions-An Epigenetic Paradigm.

Authors:  Farhat Afrin; Inbesat Khan; Hassan A Hemeg
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

6.  Network-Based Approaches Reveal Potential Therapeutic Targets for Host-Directed Antileishmanial Therapy Driving Drug Repurposing.

Authors:  J Eduardo Martinez-Hernandez; Zaynab Hammoud; Alessandra Mara de Sousa; Frank Kramer; Rubens L do Monte-Neto; Vinicius Maracaja-Coutinho; Alberto J M Martin
Journal:  Microbiol Spectr       Date:  2021-10-20

7.  (-)-T-Cadinol-a Sesquiterpene Isolated From Casearia sylvestris (Salicaceae)-Displayed In Vitro Activity and Causes Hyperpolarization of the Membrane Potential of Trypanosoma cruzi.

Authors:  Augusto L Dos Santos; Maiara Amaral; Flavia Rie Hasegawa; João Henrique G Lago; Andre G Tempone; Patricia Sartorelli
Journal:  Front Pharmacol       Date:  2021-11-03       Impact factor: 5.810

8.  Antileishmanial Efficacy of the Calpain Inhibitor MDL28170 in Combination with Amphotericin B.

Authors:  Marta H Branquinha; Pedro S S Araújo; Simone S C Oliveira; Leandro S Sangenito; Diego S Gonçalves; Sérgio H Seabra; Claudia M d'Avila-Levy; André L S Santos
Journal:  Trop Med Infect Dis       Date:  2022-02-16

9.  In Leishmania major, the Homolog of the Oncogene PES1 May Play a Critical Role in Parasite Infectivity.

Authors:  Miriam Algarabel; Celia Fernández-Rubio; Katerina Musilova; José Peña-Guerrero; Andrés Vacas; Esther Larrea; Paul A Nguewa
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.